



2013-02-11

PRESS RELEASE

## Oasmia Pharmaceutical strengthens its management team

Oasmia is in an exciting phase with product candidates in late stage development and with applications made for market approval. With the intention to make management more effective, four more persons are added to the management team.

Margareta Eriksson (born 1952) has been with Oasmia since 2008, first as clinical research manager and was in 2010 appointed to Vice President Clinical Development. She has a BSc Chemistry and Biology, PhD Zoology and has further academic education in Pharmacology, Statistics, Computer science and English. Margareta has 30 years of experience within international pharmaceutical industry as manager and project leader in clinical research.

Ingela Hägglund (born 1964) joined Oasmia in 2013 as Vice President Operations. Ingela has a PhD in Analytical Chemistry and has 18 years of experience within international pharmaceutical industry as manager and project leader in research and development of pharmaceutical products. In her area of responsibility, Operations, works 30 employees out of the close to 80 employees that Oasmia has.

Mikael Asp (born 1962) joined Oasmia in 2013 as Head of Quality Assurance. Mikael has a Master of Science in Chemical Engineering and has 25 years of experience from several companies within international pharmaceutical industry in research and development, production, quality assurance and as Qualified Person (QP).

John Cosby (born 1962) has been with Oasmia since 2006 and is Head of Regulatory Affairs. John has a BSc, Chemistry at the University of Maryland, USA. He has 30 years' experience from several companies within international life science, with responsibility for regulatory affairs and product development.

### About Oasmia Pharmaceutical AB

(NASDAQ OMX: OASM) (General Standard of Frankfurt Stock Exchange: OMAX, ISIN SE0000722365) Oasmia Pharmaceutical AB develops new generations of drugs within human and veterinary oncology. The Company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The Company's product development is based on its proprietary in-house research and company patents. The Company's common stock is listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange.

---

For more information, please contact: Johan Edin, acting Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: [press@oasmia.com](mailto:press@oasmia.com) Phone: +46 (0) 18 50 54 40. German contact: Dr. Sönke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt E-Mail: [oasmia@edicto.de](mailto:oasmia@edicto.de) Phone: +49 (0) 69 90 55 05 51. Information is also available at [www.oasmia.com](http://www.oasmia.com) [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com) [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de) [twitter.com/oasmia](http://twitter.com/oasmia)

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 09.00 a.m. CET on February 11."